Literature DB >> 7225409

Evidence for alpha-1-acid glycoprotein populations of different pI values after concanavalin A affinity chromatography. Study of their evolution during inflammation in man.

I Nicollet, J P Lebreton, M Fontaine, M Hiron.   

Abstract

Isoelectric focusing in polyacrylamide gel was used to reveal the two alpha 1-acid glycoprotein populations separated by affinity chromatography on Con A-Sepharose from human purified alpha 1-acid glycoprotein, whole normal serum and sera from patients undergoing an acute inflammatory process. The concanavalin A non-reactive peak had a lower isoelectric point than did the concanavalin A reactive peak. Moreover, crossed immunoaffinity electrophoresis with free concanavalin A revealed three alpha 1-acid glycoprotein populations (concanavalin A reactive, weakly and non-reactive). A significant difference was observed between the patterns of normal and of inflammatory sera, since the concanavalin A reactive fraction was enhanced during the inflammatory process. These results suggest a variation in relative ratios of the different types of peripheral oligosaccharide branches in the alpha 1-acid glycoprotein populations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7225409     DOI: 10.1016/0005-2795(81)90031-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  30 in total

1.  Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.

Authors:  M J Treuheit; C E Costello; H B Halsall
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice.

Authors:  W van Dijk; O Pos; M E van der Stelt; H J Moshage; S H Yap; L Dente; P Baumann; C B Eap
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

3.  Changes in the serum concentration and the glycosylation of human alpha 1-acid glycoprotein and alpha 1-protease inhibitor in severely burned persons: relation to interleukin-6 levels.

Authors:  O Pos; M E van der Stelt; G J Wolbink; M W Nijsten; G L van der Tempel; W van Dijk
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

4.  Comparative study of asparagine-linked glycans of plasma T-kininogen in normal rats and during acute inflammation.

Authors:  T Baussant; C Alonso; J M Wieruszeski; G Strecker; J Montreuil; F Alhenc-Gelas; J C Michalski
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

5.  Variations in the rate of secretion of different glycosylated forms of rat alpha 1-acid glycoprotein.

Authors:  A Drechou; J D Rouzeau; J Feger; G Durand
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

6.  Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines.

Authors:  A Mackiewicz; D Schultz; J Mathison; M Ganapathi; I Kushner
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

7.  The effects of 17 alpha-ethynyloestradiol and of acute inflammation on the plasma concentration of rat alpha 1-acid glycoprotein and on the induction of its hepatic mRNA.

Authors:  M Diarra-Mehrpour; J Bourguignon; I Leroux-Nicollet; D Marko-Vercaigne; D Biou; M Hiron; J P Lebreton
Journal:  Biochem J       Date:  1985-02-01       Impact factor: 3.857

8.  Prevalence of tri- and tetraantennary glycans of human alpha 1-acid glycoprotein in release of macrophage inhibitor of interleukin-1 activity.

Authors:  P N Bories; J Feger; N Benbernou; J D Rouzeau; J Agneray; G Durand
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

9.  The human hepatoma Hep3B cell line as an experimental model in the study of the long-term regulation of acute-phase proteins by cytokines.

Authors:  M Hiron; M Daveau; P Arnaud; J Bauer; J P Lebreton
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

10.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.